When Local Treatment Reaches a Plateau: Why More Cancer and Rare Disease Patients Are Turning to Asia’s Medical Hubs

By:DengYue International Business Division

For most patients, seeking medical care abroad is never the first choice.

When a disease is first diagnosed, people naturally place their trust in familiar healthcare systems, local physicians, and nearby hospitals. This is both the most natural and the most reasonable decision.

However, for some cancer and rare disease patients, the course of illness does not always follow expectations.

Surgery has been completed.

Chemotherapy has ended.

Targeted therapies have been tried.

Some patients have even changed hospitals multiple times.

Yet the disease continues to progress, or a clear diagnosis remains elusive.

At that point, patients begin asking a different question:

If I continue down the same treatment path, will the outcome remain the same?

More international patients are paying attention to Asia’s medical hubs not because they want to leave their home countries, but because they hope to gain access to more options when their disease becomes increasingly complex.

For Cancer Patients, the Greatest Risk Is Often Not Making the Wrong Choice—But Missing the Opportunity

Many people assume that the purpose of overseas medical care is to access more advanced medications.

In reality, for patients facing complex cancers, the more critical issue is often time.

Cancer does not stop progressing while patients are considering their next treatment step.

Once a treatment approach loses effectiveness, the window for the next opportunity may be limited.

For patients with advanced-stage cancer, this time pressure can be especially significant.

Many spend months consulting different hospitals and specialists in search of additional answers after their disease changes course.

During that period, however, the disease itself may continue to evolve.

This is one reason why more international patients seek a Second Opinion when treatment reaches a plateau.

What they are looking for is not a miracle.

They want answers to questions such as:

● Is the current diagnosis completely accurate?

● Are there other established treatment pathways available?

● Could any treatment opportunities have been overlooked?

● Should pathology findings or genetic testing results be re-evaluated?

For complex diseases, a comprehensive expert assessment can sometimes be more valuable than simply switching medications.

Why Are More Patients Looking Toward Asia?

Over the past decade, Asia has become one of the fastest-growing medical tourism markets in the world.

However, international patients are not coming to Asia solely because of cost considerations.

What truly attracts them is the unique expertise that has developed in specific disease areas.

For many patients, an important question is:

Where can I find doctors who have treated more patients like me?

Medical technologies can be learned.

Equipment can be purchased.

But experience takes years to accumulate.

And for complex diseases, experience is often one of the most valuable medical resources available.

In Certain Cancer Types, Asia Holds Some of the World’s Most Concentrated Clinical Experience

Take liver cancer as an example.

According to data from the International Agency for Research on Cancer (IARC), the majority of global liver cancer cases occur in Asia.

In countries such as China, Japan, South Korea, and several Southeast Asian nations, liver cancer has long been a major focus of clinical research and treatment.

What does this mean?

It means that many oncology centers across Asia manage a large number of complex liver cancer cases every year.

For physicians, there is a significant difference between treating 20 liver cancer cases annually and treating 2,000.

Similar patterns can also be seen in:

● Gastric cancer

● Nasopharyngeal carcinoma

● Cholangiocarcinoma (bile duct cancer)

● EGFR-mutated lung cancer

● Various gastrointestinal malignancies

For international patients, crossing borders is not simply about changing hospitals.

It is about finding medical teams with extensive experience managing similar cases.

When disease becomes more complex, experience itself becomes a form of treatment resource.

Many Patients Come to Asia Not to Find New Drugs, but to Find New Treatment Perspectives

Many people assume that overseas medical care is primarily about accessing medications unavailable in their home countries.

In many cases, however, the medications themselves may not be fundamentally different.

The real difference lies in treatment strategy.

The same cancer.

The same stage.

Yet different medical teams may recommend entirely different approaches.

For example, a patient with advanced liver cancer may receive primarily drug-based treatment in one healthcare system.

Meanwhile, an experienced oncology center in Asia may consider a combination of:

● Targeted therapy

● Immunotherapy

● Interventional oncology procedures

● Tumor ablation therapies

● Multidisciplinary Team (MDT) consultations

These approaches are not necessarily alternatives to one another.

Instead, they can be combined and tailored based on the patient’s specific condition.

For patients who have already undergone multiple lines of treatment, one additional evidence-based and clinically validated strategy may represent a new opportunity.

In addition, many patients assume that every physician reviewing the same medical records will reach the same conclusion.

In reality, that is not always the case.

As precision medicine continues to evolve, treatment decisions increasingly rely on pathology findings, molecular diagnostics, and genetic testing.

Different expert teams may interpret the same information differently.

International studies have shown that among cancer patients seeking second opinions, a significant proportion receive alternative treatment recommendations, and some even experience changes in diagnosis.

This does not necessarily mean the original diagnosis was incorrect.

Rather, it reflects the fact that complex diseases often present multiple possible pathways.

For many patients, a change in treatment direction occurs not because a new drug is discovered, but because a new perspective is gained.

Why Are More International Patients Choosing China as a Key Medical Destination in Asia?

If Asia is becoming an important global center for medical tourism, China is rapidly emerging as one of its fastest-growing destinations.

The reasons are straightforward.

First, China has one of the largest cancer patient populations in the world.

This vast patient volume enables physicians to accumulate substantial clinical experience and continuously refine treatment approaches.

Second, China has made significant advances in precision medicine, genetic testing, interventional oncology, and immunotherapy.

An increasing number of medical institutions now offer integrated systems covering diagnosis, treatment, and long-term follow-up care.

For international patients, traveling to China does not necessarily mean abandoning their existing treatment plans.

More often, they seek a different clinical perspective and an opportunity to explore additional options.

In recent years, patients from the Middle East, Southeast Asia, Europe, and other regions have traveled to Guangzhou RoyalLee Cancer Hospital for medical consultation and treatment recommendations.

Importantly, many of these patients have already undergone treatment in their home countries.

They are not coming to China to start over.

They are coming to answer one question:

“Do I still have other options?”

As a specialized oncology institution, Guangzhou RoyalLee Cancer Hospital has accumulated extensive experience in treating liver cancer, lung cancer, gastric cancer, breast cancer, pancreatic cancer, and other complex malignancies.

The hospital utilizes a Multidisciplinary Team (MDT) approach, bringing together specialists from radiology, pathology, medical oncology, surgical oncology, and related disciplines to evaluate each patient’s condition.

For international patients, the greatest value often lies not merely in receiving treatment, but in obtaining expert insights based on extensive clinical experience when facing difficult treatment decisions.

For Rare Disease Patients, the Value Asia Offers May Be an Answer

Cancer patients usually know what disease they are facing.

For many rare disease patients, however, the greatest challenge is obtaining a diagnosis at all.

They may have consulted multiple departments.

Undergone countless tests.

Yet still remain without a clear answer.

In recent years, many medical centers across Asia have expanded capabilities in:

● Whole Exome Sequencing (WES)

● Whole Genome Sequencing (WGS)

● Molecular pathology diagnostics

● Genetic counseling services

● Multidisciplinary rare disease clinics

For many families, an accurate diagnosis represents a new beginning.

Because only by understanding the disease can patients begin pursuing the right treatment path.

The essence of cross-border healthcare is not purchasing a single treatment.

It is gaining access to more evidence-based options.

For cancer patients, this may mean discovering new treatment pathways.

For rare disease patients, it may mean obtaining a definitive diagnosis.

For complex cases, it may mean receiving a second opinion from highly experienced medical teams.

Medicine can never guarantee outcomes.

But for patients who have reached a treatment plateau, the greatest regret is often not trying and failing.

It is never exploring the options that may still exist.

DengYueMed: Helping Patients Find the Right Medical Resources

When facing a complex disease, the challenge is rarely a lack of information.

More often, it is an overwhelming abundance of information.

The internet is filled with treatment options, hospital profiles, and patient success stories.

The real challenge is determining:

● Which information is relevant to a specific condition?

● Which hospitals truly have the necessary expertise?

● Which treatment options are worth further evaluation?

DengYueMed provides free medical consultation services for international patients, assisting with medical record organization, hospital matching, and cross-border treatment planning.

The goal is to help patients gain clearer insights before making important healthcare decisions.

Conclusion

More international patients are choosing Asia not because it is cheaper, and not because it promises miracles.

What attracts them is the region’s extensive clinical experience in specific diseases, mature multidisciplinary treatment systems, and alternative approaches to complex medical challenges.

When patients reach the most difficult stage of their healthcare journey, what they often need is not more hospitals—but more validated possibilities.

And that is precisely why Asia’s medical hubs are becoming increasingly important destinations for global medical tourism.